Table 1.
Type | Physiological function | Therapeutic function | Pathological function | References |
---|---|---|---|---|
ESCs | Self-renewal and expansion | Enhancing survival and expansion of HPSCs | [56–58] | |
Inducing gene expression changes in Muller cells of the retina | [59] | |||
Wound recovery | [60] | |||
| ||||
MSCs | Promoting MSCs proliferation | Repairing injured issues like heart, lung, and kidney | Promoting tumor growth | [17, 62–68] |
Cutaneous wound healing, TBI, and stroke | [69–71] | |||
Exerting immunomodulatory role on lymphocyte subsets | [72, 73] | |||
Allogenetic cell-based therapy | [74] | |||
Delivering drugs | [75, 76] | |||
Antitumor | [77–79] | |||
Promoting NPCs differentiation | [80] | |||
| ||||
NSCs | Regulating NSCs proliferation | Antibody targeting exosomes that may reduce viral infection | Neuropathological development of NSCs | [81–84] |
Triggering autoimmunity | [85] | |||
| ||||
EPCs | Promoting endothelial survival | Protecting human islets | [86, 87] | |
Steering angiogenesis in acute kidney injury | [87] | |||
Promoting angiogenesis in hindlimb ischemia | [88] | |||
Protecting H/R induced endothelial cell injury | [89] | |||
Protecting cardiomyocytes | [90] | |||
| ||||
HSCs | Maintaining stem cell property | Increasing survival of endothelial cells | [91–93] | |
MVs of CD133+ cells derived from hematopoietic tissues promote angiogenesis | [92] | |||
Vaccines for LEX that may enhance survival of patients with leukemia | [94] | |||
| ||||
CPCs | Self-renewal and differentiation | Cardioprotection promoting migration of endothelial cells |
[95–97] [15] |
Note: ESCs: embryonic stem cells; HPSCs: hematopoietic progenitor cells; MSCs: mesenchymal stem cells; TBI: traumatic brain injury; NPCs: neural progenitor cells; NSCs: neural stem cells; EPCs: endothelial progenitor cells; H/R: hypoxia/reoxygenation; HSCs: hematopoietic stem cells; MVs: microvesicles; LEX: leukemia cell-derived exosomes; CPCs: cardiac progenitor cells.